• Ambizas EM, Ginzburg R (2007). Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother 41: 957964.
  • Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S et al. (2007). Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133: 761768.
  • Bassil AK, Jarvie EM, Borman RA, Lee K, Sanger GJ (2006). Activation of EP1 receptors by lubiprostone in rat isolated forestomach longitudinal muscle. (abstract). Proc Br Pharmacol Soc 4 abstract 118P (at
  • Bassil AK, Thangiah R, Borman RA, Jarvie EM, Vivekanandan S, Lalude O et al. (2007). Effect of lubiprostone on rat and human colon muscle; possible involvement of prostaglandin Ep receptors. Gastroenterology 4 (Suppl 2): A455. abstract M2123.
  • Breault GA, Oldfield J, Tucker H, Warner P (1996). Aromatic amino ethers as pain relieving agents. Patent number WO9603380A1.
  • Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K et al. (2006a). Effect of a chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in humans (vol 17, page 602, 2005) Neurogastroenterol Motil 18: 496.
  • Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K et al. (2006b). Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol 290: G942G947.
  • Cuppoletti J, Malinowska DH, Tewari KP, Li Q, Sherry AM, Patchen ML et al. (2004). SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol 287: C1173C1183.
  • Holzer P (2006). Efferent-like roles of afferent neurons in the gut: blood flow regulation and tissue protection. Auton Neurosci 125: 7075.
  • Hussar DA (2007). New drugs 07, part I. Nursing 37: 5158.
  • Juteau H, Gareau Y, Labelle M, Sturino CF, Sawyer N, Tremblay N et al. (2001). Structure–activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. Bioorg Med Chem 9: 19771984.
  • Kan KK, Jones RL, Ngan MP, Rudd JA (2002). Actions of prostanoids to induce emesis and defecation in the ferret. Eur J Pharmacol 453: 299308.
  • Kan KK, Jones RL, Ngan MP, Rudd JA (2004). Excitatory action of prostanoids on the ferret isolated vagus nerve preparation. Eur J Pharmacol 491: 3741.
  • Marshall FH, Patel K, Lundstrom K, Camacho J, Foord SM, Lee MG (1997). Characterization of [3H]-prostaglandin E2 binding to prostaglandin EP4 receptors expressed with semiliki forest virus. Br J Pharmacol 121: 16731678.
  • Northey A, Denis D, Cirino M, Metters KM, Nantel F (2000). Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract. Prostaglandins Other Lipid Mediat 62: 145156.
  • Parentesis GP, Crawford DF, Engelke KJ, Osama H, Ueno R (2005). Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle (abstract). Neurogastroenterol Motil 17: 625.
  • Sametz W, Hennerbichler S, Glaser S, Wintersteiger R, Juan H (2000). Characterization of prostanoid receptors mediating actions of the isoprostanes, 8-iso-PGE(2) and 8-iso-PGF(2 alpha), in some isolated smooth muscle preparations. Br J Pharmacol 130: 19031910.
  • Ueno R, Osama H, Habe T, Engelke K, Patchen M (2004). Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels (Abstract). Gastroenterology 126 (Suppl 2): A298.
  • Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ et al. (2006). GW627368X ((N-{2-[4-(4, 9-diethoxy-1-oxo-1, 3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol 148: 326339.